1019 related articles for article (PubMed ID: 17947720)
21. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
22. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
23. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
Hottinger AF; DeAngelis LM; Yahalom J; Abrey LE
Neurology; 2007 Sep; 69(11):1178-82. PubMed ID: 17846417
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
Yoon DH; Lee DH; Choi DR; Sohn BS; Kim S; Kim SW; Lee JS; Lee SW; Huh J; Suh C
Bone Marrow Transplant; 2011 Jan; 46(1):105-9. PubMed ID: 20383213
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
26. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
Ferreri AJ; Verona C; Politi LS; Chiara A; Perna L; Villa E; Reni M
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):169-75. PubMed ID: 20584577
[TBL] [Abstract][Full Text] [Related]
27. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
29. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
[TBL] [Abstract][Full Text] [Related]
30. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
[TBL] [Abstract][Full Text] [Related]
31. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
32. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
[TBL] [Abstract][Full Text] [Related]
33. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
34. Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study.
Ogawa K; Yoshii Y; Toita T; Saito A; Kakinohana Y; Iraha S; Sugimoto K; Tsuchida Y; Tamaki W; Adachi G; Hyodo A; Murayama S
Anticancer Res; 2006; 26(3B):2457-62. PubMed ID: 16821632
[TBL] [Abstract][Full Text] [Related]
35. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.
Nguyen PL; Chakravarti A; Finkelstein DM; Hochberg FH; Batchelor TT; Loeffler JS
J Clin Oncol; 2005 Mar; 23(7):1507-13. PubMed ID: 15735126
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
37. [Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases].
Yue X; Zang QC
Ai Zheng; 2004 Dec; 23(12):1671-6. PubMed ID: 15601558
[TBL] [Abstract][Full Text] [Related]
38. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Colombat P; Lemevel A; Bertrand P; Delwail V; Rachieru P; Brion A; Berthou C; Bay JO; Delepine R; Desablens B; Camilleri-Broët S; Linassier C; Lamy T
Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
[TBL] [Abstract][Full Text] [Related]
39. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
40. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
